---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-163496"
form_type: "8-K"
ticker: null
cik: "0001580063"
company_name: "BIORA THERAPEUTICS, INC."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T04:57:21.658049+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biora Therapeutics cures Nasdaq listing deficiency; stock to remain on Global Market

## Summary
- Nasdaq confirmed Biora cured noncompliance with $50M total assets and $50M total revenue continued listing requirement.
- The matter is closed; common stock remains listed on The Nasdaq Global Market.
- Letter received June 8, 2023; no further action needed from Company.

## SEC filing metadata
- accession: 0001193125-23-163496
- form_type: 8-K
- cik: 0001580063
- company_name: BIORA THERAPEUTICS, INC.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580063/000119312523163496/0001193125-23-163496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580063/000119312523163496/d574823d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-163496
- JSON: https://secwatch.observer/filing/0001193125-23-163496.json
- Plain text: https://secwatch.observer/filing/0001193125-23-163496.txt

## Key facts
- Listing & Compliance Notices
  BIORA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding other.
  - Exchange: nasdaq
  - Notice: compliance regained
  source text: June 8, 2023, Biora Therapeutics, Inc. (the “ Company ”) received a letter (the “ Compliance Letter ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Company’s previously announced noncompliance with the $50 million in total assets and $50 million in total revenue requirement for continued listing on The Nasdaq Global Market has been cured. Accordingly, the Compliance Letter provided that the matter has been closed with Nasdaq. The Company’s common stock will continue to be listed and traded on The Nasdaq Global Market. SIGNATUR
  evidence_url: https://www.sec.gov/Archives/edgar/data/1580063/000119312523163496/0001193125-23-163496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.